Back to top
more

CanFite Biopharma (CANF)

(Delayed Data from AMEX)

$1.97 USD

1.97
8,737

-0.01 (-0.51%)

Updated Apr 29, 2024 03:59 PM ET

After-Market: $1.97 0.00 (0.00%) 5:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CANF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Can-Fite Biopharma Ltd [CANF]

Reports for Purchase

Showing records 41 - 60 ( 216 total )

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 41

01/07/2022

Company Report

Pages: 5

Looking to 1H22 for Major Catalysts; Reiterate Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 42

01/05/2022

Company Report

Pages: 6

BUY-Rated: Expected Milestones

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 43

12/20/2021

Company Report

Pages: 6

BUY-Rated: A Cure in One Patient with Liver Cancer?

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 44

12/20/2021

Daily Note

Pages: 3

5 Years and Counting Complete Response Observed With Namodenoson

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 45

12/07/2021

Company Report

Pages: 6

BUY-Rated - Top-Line Data in January

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 46

12/07/2021

Company Report

Pages: 6

BUY-Rated Top-Line Data in January

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 47

12/02/2021

Company Report

Pages: 5

Piclidenoson and Namodenoson Are on Track for an Eventful 2022; Reiterate Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 48

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for CANF

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 49

08/27/2021

Company Report

Pages: 6

BUY-Rated Going Pivotal in Liver Cancer

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 50

07/08/2021

Company Report

Pages: 6

BUY-Rated - Going Pivotal in Liver Cancer

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 51

06/07/2021

Company Report

Pages: 5

Clinical Program Advancement Backed by a Growing Number of Distribution Agreements

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 52

06/04/2021

Company Report

Pages: 6

BUY-Rated -NASH is 2b

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 53

05/27/2021

Company Report

Pages: 6

BUY-Rated -Funded through Catalysts

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 54

04/29/2021

Company Report

Pages: 6

BUY-Rated -Piclidenoson Trial Hits the ¾ Mark

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 55

04/22/2021

Company Report

Pages: 5

BUY-Rated - COVID Study Expands to Europe

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 56

03/29/2021

Company Report

Pages: 6

BUY-Rated - Reports 2020 - Milestones Ahead

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 57

03/26/2021

Company Report

Pages: 5

2020 a Year of Robust Clinical Proof-of-Concept Demonstration With Piclidenoson and Namodenoson; Reit Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 58

03/16/2021

Company Report

Pages: 6

BUY Rated: Ewopharma Cuts a Deal After Six Months of Diligence

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 59

03/16/2021

Daily Note

Pages: 3

Strategic Deal Maintains Freedom to Operate in Larger Territories; Reiterate Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 60

03/05/2021

Company Report

Pages: 6

BUY Rated - Phase 2 COVID Study is Underway

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party